2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension (Q42849832)

8 November 2017

title

2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension (English)

1 reference

8 November 2017

10

1 reference

8 November 2017

Tzung-Dau Wang

2

0 references

Fu-Tien Chiang

object named as

Fu-Tien Chiang

11

0 references

Kuo-Liong Chien

object named as

Kuo-Liong Chien

5

0 references

Kou-Gi Shyu

7

object named as

Kou-Gi Shyu

1 reference

8 November 2017

Chern-En Chiang

1

1 reference

8 November 2017

Yi-Heng Li

3

1 reference

8 November 2017

Tsung-Hsien Lin

4

1 reference

8 November 2017

Hung-I Yeh

6

1 reference

8 November 2017

Wei-Chuen Tsai

8

1 reference

8 November 2017

Ting-Hsing Chao

9

1 reference

8 November 2017

Jyh-Hong Chen

12

1 reference

8 November 2017

Hypertension Committee of the Taiwan Society of Cardiology

13

1 reference

8 November 2017

publication date

1 October 2010

1 reference

Journal of the Formosan Medical Association

8 November 2017

published in

1 reference

8 November 2017

volume

109

1 reference

8 November 2017

issue

10

1 reference

8 November 2017

page(s)

740-773

1 reference

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Global burden of blood-pressure-related disease, 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Hypertension in the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Evidence for improved control of hypertension in Taiwan: 1993-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The burden of blood pressure-related disease: a neglected priority for global health

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Essential Hypertension : Part I: Definition and Etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Genome-wide association study of blood pressure and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Genome-wide association study identifies eight loci associated with blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Secondary hypertension: current diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Ambulatory blood-pressure monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Why Is Out-of-Office Blood Pressure Measurement Needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The Long-term Prognostic Significance of Repeated Blood Pressure Measurements in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Systolic pressure is all that matters

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Systolic and diastolic blood pressure control in antihypertensive drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The optimal schedule for self-monitoring of blood pressure by patients at home.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

What is the optimal interval between successive home blood pressure readings using an automated oscillometric device?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Resistant hypertension, secondary hypertension, and hypertensive crises

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

High incidence of primary aldosteronism in 199 patients referred with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Adherence to healthy lifestyle habits in US adults, 1988-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Urinary sodium and potassium excretion and risk of hypertension in Chinese: report from a community-based cohort study in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Potential societal savings from reduced sodium consumption in the U.S. adult population

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Projected effect of dietary salt reductions on future cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Non-pharmacological treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Essential hypertension : part II: treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Controversies in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Treatment of non-dipper hypertension with bedtime administration of valsartan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Compliance with antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Hypertension and the "J-curve"

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Clinical practice. Resistant or difficult-to-control hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Standards of medical care in diabetes--2009.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Beta-blockers for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertensio

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Fixed-dose combinations improve medication compliance: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Executive summary: Standards of medical care in diabetes--2010

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the A

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Successful blood pressure control in the African American Study of Kidney Disease and Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Blood pressure and cardiovascular disease in the Asia Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Relation of Blood Pressure and All-Cause Mortality in 180 000 Japanese Participants

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Drug treatment of hypertension in the elderly: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Systolic blood pressure and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

In a population-based prospective study, no association between high blood pressure and mortality after age 85 years

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Long term hormone therapy for perimenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Management of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Clinical features in the management of selected hypertensive emergencies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

1 reference

7 January 2021

Prevalence of Renovascular Hypertension in Patients with Grade III or IV Hypertensive Retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Resistant hypertension: an overview of evaluation and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Resistant hypertension revisited: a comparison of two university-based cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Electrophysiological Study of the Striated Muscle Cells of Extrapulmonary Vein of Guinea-Pig

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960120-9

7 January 2021

10.1016/S0929-6646(10)60120-9

Identifiers

DOI

1 reference

8 November 2017

1 reference